139
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Characteristics of 12-Month Readmission for Hospitalized Patients with COPD: A Propensity Score Matched Analysis of Prospective Multicenter Study

, , , , , , , , , , ORCID Icon, & show all
Pages 2329-2341 | Received 01 Jun 2022, Accepted 09 Sep 2022, Published online: 20 Sep 2022

References

  • Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. Lancet Respir Med. 2022;10(5):485–496. doi:10.1016/s2213-2600(21)00510-5
  • Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. doi:10.1111/all.13760
  • Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/s0140-6736(19)30427-1
  • Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52(5):1801261. doi:10.1183/13993003.01261-2018
  • Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/s0140-6736(17)31222-9
  • Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679. doi:10.1136/bmj-2021-069679
  • Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP
  • Global Initiative for Chronic Obstructive Lung Disease. 2020 Report: global strategy for prevention, diagnosis and management of COPD; 2020.
  • Zemans RL, Jacobson S, Keene J, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117. doi:10.1186/s12931-017-0597-7
  • García-Sanz MT, Cánive-Gómez JC, Senín-Rial L, et al. One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease. J Thorac Dis. 2017;9(3):636–645. doi:10.21037/jtd.2017.03.34
  • Alqahtani JS, Aldabayan YS, Aldhahir AM, Al Rajeh AM, Mandal S, Hurst JR. Predictors of 30- and 90-day COPD exacerbation readmission: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:2769–2781. doi:10.2147/copd.S328030
  • Alqahtani JS, Njoku CM, Bereznicki B, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020;29:156. doi:10.1183/16000617.0166-2019
  • Njoku CM, Alqahtani JS, Wimmer BC, et al. Risk factors and associated outcomes of hospital readmission in COPD: a systematic review. Respir Med. 2020;173:105988. doi:10.1016/j.rmed.2020.105988
  • Kim VL, Coombs NA, Staples KJ, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017;50(4):1700853. doi:10.1183/13993003.00853-2017
  • Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/s2213-2600(17)30432-0
  • Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC
  • David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
  • MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest. 2019;156(1):92–100. doi:10.1016/j.chest.2019.02.406
  • Jabarkhil A, Moberg M, Janner J, et al. Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. Eur Clin Respir J. 2020;7(1):1757274. doi:10.1080/20018525.2020.1757274
  • Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y
  • Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC
  • Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936. doi:10.1136/bmj.m1936
  • Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
  • Koreny M, Arbillaga-Etxarri A, de Basea MB, et al. Urban environment and physical activity and capacity in patients with chronic obstructive pulmonary disease. Environ Res. 2022;214:113956. doi:10.1016/j.envres.2022.113956
  • Mir WAY, Siddiqui AH, Paul V, et al. Palliative care and Chronic Obstructive Pulmonary Disease (COPD) readmissions: a narrative review. Cureus. 2021;13(8):e16987. doi:10.7759/cureus.16987
  • Le Rouzic O, Roche N, Cortot AB, et al. Defining the ”Frequent Exacerbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018;153(5):1106–1115. doi:10.1016/j.chest.2017.10.009
  • Hoffmann RF, Jonker MR, Brandenburg SM, et al. Mitochondrial dysfunction increases pro-inflammatory cytokine production and impairs repair and corticosteroid responsiveness in lung epithelium. Sci Rep. 2019;9(1):15047. doi:10.1038/s41598-019-51517-x
  • O’Beirne SL, Shenoy SA, Salit J, et al. Ambient pollution-related reprogramming of the human small airway epithelial transcriptome. Am J Respir Crit Care Med. 2018;198(11):1413–1422. doi:10.1164/rccm.201712-2526OC
  • Brandsma CA, de Vries M, Costa R, Woldhuis RR, Königshoff M, Timens W. Lung ageing and COPD: is there a role for ageing in abnormal tissue repair? Eur Respir Rev. 2017;26(146):170073. doi:10.1183/16000617.0073-2017
  • Karakioulaki M, Papakonstantinou E, Stolz D. Extracellular matrix remodelling in COPD. Eur Respir Rev. 2020;29(158):190124. doi:10.1183/16000617.0124-2019
  • Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935. doi:10.1056/NEJMoa1700228
  • Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/s2213-2600(17)30207-2
  • Thomashow B, Stiegler M, Criner GJ, et al. Higher COPD assessment test score associated with greater exacerbations risk: a post hoc analysis of the IMPACT trial. Chronic Obstr Pulm Dis. 2022;9(1):68–79. doi:10.15326/jcopdf.2021.0259
  • Pulido Herrero E, García Gutiérrez S, Antón Ladislao A, et al. Chronic obstructive pulmonary disease assessment test: usefulness for monitoring recovery and predicting poor course of disease after exacerbations. Emergencias. 2019;31(1):21–26.
  • Cookson W, Moffatt M, Rapeport G, Quint J, Pandemic A. Lesson for global lung diseases: exacerbations are preventable. Am J Respir Crit Care Med. 2022;205(11):1271–1280. doi:10.1164/rccm.202110-2389CI
  • Wang MT, Lai JH, Huang YL, et al. Comparative effectiveness and safety of different types of inhaled long-acting β(2)-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β(2)-agonist plus inhaled corticosteroid fixed-dose combinations in COPD A propensity score-inverse probability of treatment weighting cohort study. Chest. 2021;160(4):1255–1270. doi:10.1016/j.chest.2021.05.025
  • Chen L, Chen S. Prediction of readmission in patients with acute exacerbation of chronic obstructive pulmonary disease within one year after treatment and discharge. BMC Pulm Med. 2021;21(1):320. doi:10.1186/s12890-021-01692-3
  • Celli B, Locantore N, Yates JC, et al. Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. Eur Respir J. 2021;57(3). doi:10.1183/13993003.01339-2020
  • Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462. doi:10.2147/copd.S157779
  • Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230. doi:10.1183/13993003.01230-2018
  • Martínez-Gestoso S, García-Sanz MT, Calvo-álvarez U, et al. Variability of blood eosinophil count and prognosis of COPD exacerbations. Ann Med. 2021;53(1):1152–1158. doi:10.1080/07853890.2021.1949489
  • Ferguson GT, Shaikh A, Tetzlaff K, Mueller A, Magnussen H, Watz H. Effect of inhaled corticosteroid withdrawal on chronic obstructive pulmonary disease exacerbations in patients taking triple therapy at baseline. Int J Chron Obstruct Pulmon Dis. 2020;15:2879–2888. doi:10.2147/copd.S237408
  • Dalin DA, Løkke A, Kristiansen P, et al. A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD. Respir Med. 2022;198:106880. doi:10.1016/j.rmed.2022.106880
  • Echevarria C, Steer J, Bourke SC. Comparison of early warning scores in patients with COPD exacerbation: DECAF and NEWS score. Thorax. 2019;74(10):941–946. doi:10.1136/thoraxjnl-2019-213470
  • Greulich T, Tüffers J, Mager S, et al. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis. Respir Res. 2020;21(1):106. doi:10.1186/s12931-020-01365-5
  • Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020;25(3):259–266. doi:10.1111/resp.13660
  • Choi J, Oh JY, Lee YS, et al. The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:953–959. doi:10.2147/copd.S197361
  • Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017;18(1):88. doi:10.1186/s12931-017-0570-5
  • Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709. doi:10.1016/s2213-2600(19)30176-6
  • Lonergan M, Dicker AJ, Crichton ML, et al. Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respir Res. 2020;21(1):166. doi:10.1186/s12931-020-01436-7
  • Halpin DMG, Criner GJ, Papi A, et al.; Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24–36. doi:10.1164/rccm.202009-3533SO
  • Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/s0140-6736(22)00470-6